PF4/Heparin Antibodies Predict Mortality in HIT

This article originally appeared here.
Share this content:
PF4/Heparin Antibodies Predict Mortality in HIT
PF4/Heparin Antibodies Predict Mortality in HIT

MONDAY, Jan. 11, 2016 (HealthDay News) -- Heparin-induced thrombocytopenia (HIT) is infrequent in patients undergoing cardiac surgery, but is associated with increased 30-day mortality, according to a study published in the Jan. 15 issue of The American Journal of Cardiology.

Xiumei Sun, M.D., from the Medstar Heart Institute in Washington, D.C., and colleagues examined the impact of HIT on contemporary cardiac surgical practice. A total of 14,415 consecutive patients undergoing cardiac surgery were screened postoperatively for thrombocytopenia. Those with thrombocytopenia were tested for antiplatelet factor 4 (PF4)/heparin antibodies and assessed for clinical evidence of thrombosis.

The researchers found that 13 percent of the patients had thrombocytopenia. Of these, 15 and 4 percent had PF4/heparin antibodies and antibodies and clinical thrombosis, respectively. The frequency of antibodies was elevated in women (P = 0.01), in patients with increased body mass index (P < 0.01), and in patients with preoperative clinical heart failure (P < 0.01). Among the 76 patients with the triad of thrombocytopenia, antibodies, and clinical thrombosis, 30-day mortality was highest (30 percent). The presence of PF4/heparin antibodies independently predicted 30-day mortality among patients with thrombocytopenia (odds ratio, 2.09; P < 0.001).

"HIT remains an infrequent but very serious complication of heparin therapy in contemporary cardiac surgical practice," the authors write. "The possibility that the presence of HIT antibodies in patients with thrombocytopenia independently increases operative mortality deserves further study."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »